Project SHIVOM

SHIVOM- The Global Blockchain-Genomics Ecosystem Powering the Next Era of Precision Medicine.

About Project SHIVOM

The Shivom ecosystem plans to offer an open blockchain-based genomics database alongside a web marketplace and innovation hub, which will allow providers and third-party vendors to add market-customized apps and precision-medicine services. Shivom intends to build a platform using convergent technologies including genomics, blockchain, and artificial intelligence. Upon establishing a scalable healthcare vertical, Shivom will extend its services to form a global network of genomic counselors and associated laboratories, as well as establish a non-profit R&D organization. The research institute will be based on open innovation that optimally connects patients, clinicians, researchers, insurers, labs, and other stakeholders. The Shivom platform will work on the principles of open collaboration, transparency, and integrity. Patients / donors will have full control over their sensitive personal health data, and will be able to donate or monetize on their genomes via crypto keys and Shivom’s blockchain platform.
Competitors: Proof Work, Mediledger, SimplyVital Health, Robomed Network, MedicalChain, IRYO
Uniqueness/Advantages to competition: Medical platform is aimed directly at genome data managment.

Token Sale Use of Blockchain

Product

3.2
Product
Readiness

Is the product ready for use? Is there a working prototype or MVP? How long until it is operational?

3.0
N/A
3 - Prototype / MVP / alpha.
Appeal

How appealing is the product? How good or necessary is it? Does it have a distinct edge?

3.0
N/A
3 - Interesting.
Target User Base

Is it mass market or niche?

4.0
N/A
4 - Large audience / wide market.
Competition

Are there many other similar solutions or is this one of just a few, or even one of a kind?

3.0
N/A
3 - Some normal competition.
Innovation

How innovative or inventive is the product, either conceptually or technologically?

3.0
N/A
3 - Partial, a novel approach or aspect.

Product

Shivom is meant to be blockchain-based ecosystem for genomics data. There is currently no publicly accessible github repository for the project, however it is possible to sign-up on the website to test the alpha platform. The mobile apps, beta dev/testing, and full platform launch are planned for after the ICO (see Roadmap).
There is appeal to the Shivom product, given the increasing demand for decentralized and secure storage of personal records in general and medical records in particular. The potential / target user-base will grow with natural population development (given the increasing need for medical services) and cryptocurrency adoption in the general population. There is currently some normal competition in the sector of decentralized medical marketplaces/blockchains, and blockchain competition will stiffen over time as cryptocurrency adoption continues.
Competitors: Proof Work, Mediledger, SimplyVital Health, Robomed Network, MedicalChain

Product Whitepaper

Use of Blockchain

2.6
Use of Blockchain
Blockchain Development

Is blockchain technology essential? Does it make the solution significantly different and better?

2.0
N/A
2 - Some smart contract functionality.
Disruptive Blockchain Advantage

How disruptive is the introduction of blockchain technology into the product's market space?

3.0
N/A
3 - Potentially disruptive.
Need for a Custom Token (vs. BTC or ETH)

Is the token essential or could it be done just as well or better with fiat or Bitcoin?

2.0
N/A
2 - Some, mainly network effect.
System Decentralization (besides token)

How decentralized is the system architecture other than the token (e.g., data collection, storage, access, and use, or decision making processes, etc.)?

3.0
N/A
3 - Hybrid; decentralized as far as circumstances allow.
Contribution to Blockchain Ecosystem

How compelling is the solution's contribution to the evolution of blockchain infrastructure and economy?

3.0
N/A
3 - Interesting.

Use of Blockchain

The OmiX token is ERC-20 standard and is the main utility for access to the platform, for fueling the Shivom ecosystem, and for part of the system’s governance.
Shivom’s contribution to blockchain development is in the utilization of the Ethereum blockchain for creating a new platform for medical data storage and exchange.
The project’s primary disruptive advantage is based on its use of blockchain technology to create a transparent and secure ecosystem for personal medical data storage, one that is specifically geared towards genomic data.
The need for a custom token is for payment of transaction fees and for all services within network, to power the market-efficiency mechanism, and as a tradable cryptocurrency available on the open market.
The contribution to the blockchain ecosystem is in developing a new blockchain based medical data stroage platfrom, therefore increasing the decentralization and security of personal data.

Use of Blockchain Roadmap

Whitepaper

4.0
Whitepaper
Comprehensiveness

Does it cover the full scope of the problem and solution?

5.0
N/A
5 - All issues addressed coherently.
Readability

Is it easy enough to understand?

4.0
N/A
4 - Easy to read and understand.
Transparency

Does it candidly describe and disclose where the project now stands, how much exists and how much still needs to be done, etc.?

3.0
N/A
3 - Basic honesty with some hype.
Business Plan Presentation

Does it contain a viable, comprehensive business plan?

4.0
N/A
4 - Clear, well thought out, realistic.
Technology Presentation

Does it present a well thought out technological architecture? Does it address implementational challenges?

4.0
N/A
4 - Clear, well thought out, realistic.

Whitepaper

The whitepaper is professional, very visually pleasant, informative, and provides a balanced mixture of media and textual explanation. The whitepaper is 58 pages long and is overall readable and understandable. The whitepaper includes the following sections: Abstract, Introduction, Market Overview, Offerings & Solutions, Platform Protocols & Architecture, Business Model, Sponsorships & Partnerships, OmiX: The Global Genomics Token, Roadmap, Global Leadership, and References. The business and technology plans behind Shivom are detailed and concisely explained including textual and graphical explanations. References are provided in end-note form.

Whitepaper Compliance

Roadmap

3.0
Roadmap
Concreteness

Is there a concrete and practical development plan (vs. just a conceptual vision)?

3.0
N/A
3 - An overall plan, major milestones stated.
Feasibility

Is the development plan realistic? Is it based on reasonable goals and timelines?

3.0
N/A
3 - Optimistic.
Vision

Is there a larger, long-term vision?

3.0
N/A
3 - A trend with potential.
Dependencies (services or capabilities)

How available, operational, or trusted are the other systems or capabilities on which the project relies?

4.0
N/A
4 - Available and trusted.
Current Position

Where is the project now, relative to its vision and plans?

2.0
N/A
2 - Critical obstacles ahead.

Roadmap

A vague project roadmap is given with milestones presented on a quarterly basis. Obstacles lie ahead as beta platform development/deployment, and final platform release will occur after the ICO. The roadmap provides major milestones and no descriptions of the intermediate steps required to complete each milestone.

Platform Roadmap:
Q1 2017 – Conceptualization
Q2 2017 – Seed Round
Q3 2017 – Shivom Roadshow Starts
Q1 2018 – Private round raised from major crypto vc’s / Innovation Council
Q2 2018 – Partnership with State of AP / OmiX tokens distributed / Project Gaia / Beta version platform product launch
Q3 2018 – Establishment of sequencing processes and protocols / Blockchain protocols for multiple encryption / Co-dev. of new SNP panels for rare/complex disease / Web marketplace open / First Genomic lab setup / Shivom foundation
Q4 2018 – Worldwide rollout of Shivom platform / Formation Shivom reasearch division / Multi-omics integration
Q1 2019 – AI Platform

Roadmap Company and Team

Compliance

2.6
Compliance
Token Utility (value through usage)

How much use is there for the token itself (regardless of its value as an investment vehicle)?

3.0
N/A
3 - Limited or uncertain use cases.
Token as Security (tradable instrument)

How valuable is the token as an investment vehicle or financial instrument?

2.0
N/A
2 - Primarily, with few additional rights.
Token/Smart-Contract Readiness

Is the blockchain infrastructure of the project ready for use? Is there a working prototype or MVP? How long until it is operational?

3.0
N/A
3 - Prototype / MVP / alpha.
Attention to Compliance Issues

How much attention is given to compliance (via token and ecosystem design, token sale participation, etc.)? Is this issue addressed directly and coherently?

2.0
N/A
2 - Minimal, superficial or hackneyed.
Legal Review/Risk Assessment

What kind of legal documentation (reviews or agreements) and risk assessment are provided?

3.0
N/A
3 - Semi-professional (e.g. Howey Test)

Compliance

The OmiX token is a key component of the system that enables buying, trading, and incentivizing the ecosystem. The token is the fuel of an internal mechanism of the Shivom ecosystem, as well as part of the governance component of the system. The token smart-contract code is not posted for review and there is no publicly accessible github repository but you can sign-up to use the alpha platform. Compliance is addressed with direct statements of AML & KYC Due Diligence and enforced with a registration whitelisting process, however one must only click a check box to agree that they are in compliance witht the laws of their nation. The legal review and terms and conditions of the sale aim to absolve the company of any liability regarding the ICO and any problems that may occur, and provide a general statment that the tokens are not to be deemed a security.

Compliance Token Sale

Company and Team

3.8
Company and Team
Company Stage and Foundation

Is the company already established? Has it raised funds before? Is it mature?

4.0
N/A
4 - Established with some fundraising history.
Background of Lead Team Members

Do we know who they are? Do they have LinkedIn profiles? Do they have solid, relevant backgrounds?

4.0
N/A
4 - Verifiable relevant experience.
Team Assembly and Commitment

Is a solid, fully committed core team in place? Do they have online (e.g. LinkedIn) profiles showing sufficient relevant experience? Is their participation transparent?

3.0
N/A
3 - Mostly assembled and committed.
Team Skill Set Relevance

Does the amount of talent and skill in each area seem to fit the project requirements?

4.0
N/A
4 - Well suited to project requirements.
Team Skill Set Balance

Is the team well-rounded (biz/tech/blockchain)? Is there sufficient talent and skill in all areas of required development?

4.0
N/A
4 - Good, sufficient for each aspect.

Company and Team

Shivom has an established team with 15 employees, 9 members of the Shivom Innovation Council, and 3 advisors.
The core team has experience in blockchain projects, digital health projects, fintech, ICO advisement, entrepreneurship, medicine, genomics, epigenetics, biomarker discovery, Bio-IT, aging & longevity, business development, public relations, and graphics design.
The advisors have experience in capital managment, venture capitalism, and investments.
The core team has verifiable work experience credentials via LinkedIn profiles, though some profiles provide little information. Some members of the team appear to be dedicated to other projects outside of Shivom.
Positives: The core team is well rounded and some members have previous experience with cryptocurrency/blockchain/smart-contract projects.
Negatives: Not all members may be fully dedicated to the project.

Company and Team Product

Token Sale

2.8
Token Sale
Raise Amount Max

Is there a clear cap? Is the maximum raise amount modestly sufficient (as opposed to either greedy or insufficient)?

2.0
N/A
2 - Somewhat greedy or unrelated to plans.
Raise Amount Min

Is the minimum raise reasonable considering the development plan? Are there raise-amount dependent milestones?

2.0
N/A
2 - Only loosely related to plans.
Fund Allocation

Is fund distribution and allocation reasonable and justified?

4.0
N/A
4 - Well defined and reasonable.
Token Allocation

Is the ratio of tokens sold to those kept reasonable? Does it prevent the company from having too much control?

2.0
N/A
2 - Unclear or suspicious.
Media Presence and Following

Is the sale being talked about in Reddit, Bitcointalk, Social Media, Medium, etc.? Is information available and accessible? Is there interest?

4.0
N/A
4 - Solid exposure and interest, good impression.

Token Sale

OmiX Token
Total supply: 3 Billion OmiX
Token Price: n/a
Hard Cap: n/a
Min Cap: n/a

Token Allocation
33% ICO
20% Growth Pool
20% Reserve
14% Founders
10% Advisors
03% Community

ICO Proceeds Distribution
23% Laboratories
21% Marketing
20% Platform Development
11% Operations
10% R&D
06% Data Storage
05% Legal
02% Sequencing PoC

Social Media Presence & Following
There is solid community engagment and reception.

Product

Shivom is meant to be blockchain-based ecosystem for genomics data. There is currently no publicly accessible github repository for the project, however it is possible to sign-up on the website to test the alpha platform. The mobile apps, beta dev/testing, and full platform launch are planned for after the ICO (see Roadmap).
There is appeal to the Shivom product, given the increasing demand for decentralized and secure storage of personal records in general and medical records in particular. The potential / target user-base will grow with natural population development (given the increasing need for medical services) and cryptocurrency adoption in the general population. There is currently some normal competition in the sector of decentralized medical marketplaces/blockchains, and blockchain competition will stiffen over time as cryptocurrency adoption continues.
Competitors: Proof Work, Mediledger, SimplyVital Health, Robomed Network, MedicalChain

Category Breakdown
Readiness

Is the product ready for use? Is there a working prototype or MVP? How long until it is operational?

3.0
N/A
3 - Prototype / MVP / alpha.
Appeal

How appealing is the product? How good or necessary is it? Does it have a distinct edge?

3.0
N/A
3 - Interesting.
Target User Base

Is it mass market or niche?

4.0
N/A
4 - Large audience / wide market.
Competition

Are there many other similar solutions or is this one of just a few, or even one of a kind?

3.0
N/A
3 - Some normal competition.
Innovation

How innovative or inventive is the product, either conceptually or technologically?

3.0
N/A
3 - Partial, a novel approach or aspect.
Product Score:
3.2

Use of Blockchain

The OmiX token is ERC-20 standard and is the main utility for access to the platform, for fueling the Shivom ecosystem, and for part of the system’s governance.
Shivom’s contribution to blockchain development is in the utilization of the Ethereum blockchain for creating a new platform for medical data storage and exchange.
The project’s primary disruptive advantage is based on its use of blockchain technology to create a transparent and secure ecosystem for personal medical data storage, one that is specifically geared towards genomic data.
The need for a custom token is for payment of transaction fees and for all services within network, to power the market-efficiency mechanism, and as a tradable cryptocurrency available on the open market.
The contribution to the blockchain ecosystem is in developing a new blockchain based medical data stroage platfrom, therefore increasing the decentralization and security of personal data.

Category Breakdown
Blockchain Development

Is blockchain technology essential? Does it make the solution significantly different and better?

2.0
N/A
2 - Some smart contract functionality.
Disruptive Blockchain Advantage

How disruptive is the introduction of blockchain technology into the product's market space?

3.0
N/A
3 - Potentially disruptive.
Need for a Custom Token (vs. BTC or ETH)

Is the token essential or could it be done just as well or better with fiat or Bitcoin?

2.0
N/A
2 - Some, mainly network effect.
System Decentralization (besides token)

How decentralized is the system architecture other than the token (e.g., data collection, storage, access, and use, or decision making processes, etc.)?

3.0
N/A
3 - Hybrid; decentralized as far as circumstances allow.
Contribution to Blockchain Ecosystem

How compelling is the solution's contribution to the evolution of blockchain infrastructure and economy?

3.0
N/A
3 - Interesting.
Use of Blockchain Score:
2.6

Whitepaper

The whitepaper is professional, very visually pleasant, informative, and provides a balanced mixture of media and textual explanation. The whitepaper is 58 pages long and is overall readable and understandable. The whitepaper includes the following sections: Abstract, Introduction, Market Overview, Offerings & Solutions, Platform Protocols & Architecture, Business Model, Sponsorships & Partnerships, OmiX: The Global Genomics Token, Roadmap, Global Leadership, and References. The business and technology plans behind Shivom are detailed and concisely explained including textual and graphical explanations. References are provided in end-note form.

Category Breakdown
Comprehensiveness

Does it cover the full scope of the problem and solution?

5.0
N/A
5 - All issues addressed coherently.
Readability

Is it easy enough to understand?

4.0
N/A
4 - Easy to read and understand.
Transparency

Does it candidly describe and disclose where the project now stands, how much exists and how much still needs to be done, etc.?

3.0
N/A
3 - Basic honesty with some hype.
Business Plan Presentation

Does it contain a viable, comprehensive business plan?

4.0
N/A
4 - Clear, well thought out, realistic.
Technology Presentation

Does it present a well thought out technological architecture? Does it address implementational challenges?

4.0
N/A
4 - Clear, well thought out, realistic.
Whitepaper Score:
4.0

Roadmap

A vague project roadmap is given with milestones presented on a quarterly basis. Obstacles lie ahead as beta platform development/deployment, and final platform release will occur after the ICO. The roadmap provides major milestones and no descriptions of the intermediate steps required to complete each milestone.

Platform Roadmap:
Q1 2017 – Conceptualization
Q2 2017 – Seed Round
Q3 2017 – Shivom Roadshow Starts
Q1 2018 – Private round raised from major crypto vc’s / Innovation Council
Q2 2018 – Partnership with State of AP / OmiX tokens distributed / Project Gaia / Beta version platform product launch
Q3 2018 – Establishment of sequencing processes and protocols / Blockchain protocols for multiple encryption / Co-dev. of new SNP panels for rare/complex disease / Web marketplace open / First Genomic lab setup / Shivom foundation
Q4 2018 – Worldwide rollout of Shivom platform / Formation Shivom reasearch division / Multi-omics integration
Q1 2019 – AI Platform

Category Breakdown
Concreteness

Is there a concrete and practical development plan (vs. just a conceptual vision)?

3.0
N/A
3 - An overall plan, major milestones stated.
Feasibility

Is the development plan realistic? Is it based on reasonable goals and timelines?

3.0
N/A
3 - Optimistic.
Vision

Is there a larger, long-term vision?

3.0
N/A
3 - A trend with potential.
Dependencies (services or capabilities)

How available, operational, or trusted are the other systems or capabilities on which the project relies?

4.0
N/A
4 - Available and trusted.
Current Position

Where is the project now, relative to its vision and plans?

2.0
N/A
2 - Critical obstacles ahead.
Roadmap Score:
3.0

Compliance

The OmiX token is a key component of the system that enables buying, trading, and incentivizing the ecosystem. The token is the fuel of an internal mechanism of the Shivom ecosystem, as well as part of the governance component of the system. The token smart-contract code is not posted for review and there is no publicly accessible github repository but you can sign-up to use the alpha platform. Compliance is addressed with direct statements of AML & KYC Due Diligence and enforced with a registration whitelisting process, however one must only click a check box to agree that they are in compliance witht the laws of their nation. The legal review and terms and conditions of the sale aim to absolve the company of any liability regarding the ICO and any problems that may occur, and provide a general statment that the tokens are not to be deemed a security.

Category Breakdown
Token Utility (value through usage)

How much use is there for the token itself (regardless of its value as an investment vehicle)?

3.0
N/A
3 - Limited or uncertain use cases.
Token as Security (tradable instrument)

How valuable is the token as an investment vehicle or financial instrument?

2.0
N/A
2 - Primarily, with few additional rights.
Token/Smart-Contract Readiness

Is the blockchain infrastructure of the project ready for use? Is there a working prototype or MVP? How long until it is operational?

3.0
N/A
3 - Prototype / MVP / alpha.
Attention to Compliance Issues

How much attention is given to compliance (via token and ecosystem design, token sale participation, etc.)? Is this issue addressed directly and coherently?

2.0
N/A
2 - Minimal, superficial or hackneyed.
Legal Review/Risk Assessment

What kind of legal documentation (reviews or agreements) and risk assessment are provided?

3.0
N/A
3 - Semi-professional (e.g. Howey Test)
Compliance Score:
2.6

Company and Team

Shivom has an established team with 15 employees, 9 members of the Shivom Innovation Council, and 3 advisors.
The core team has experience in blockchain projects, digital health projects, fintech, ICO advisement, entrepreneurship, medicine, genomics, epigenetics, biomarker discovery, Bio-IT, aging & longevity, business development, public relations, and graphics design.
The advisors have experience in capital managment, venture capitalism, and investments.
The core team has verifiable work experience credentials via LinkedIn profiles, though some profiles provide little information. Some members of the team appear to be dedicated to other projects outside of Shivom.
Positives: The core team is well rounded and some members have previous experience with cryptocurrency/blockchain/smart-contract projects.
Negatives: Not all members may be fully dedicated to the project.

Category Breakdown
Company Stage and Foundation

Is the company already established? Has it raised funds before? Is it mature?

4.0
N/A
4 - Established with some fundraising history.
Background of Lead Team Members

Do we know who they are? Do they have LinkedIn profiles? Do they have solid, relevant backgrounds?

4.0
N/A
4 - Verifiable relevant experience.
Team Assembly and Commitment

Is a solid, fully committed core team in place? Do they have online (e.g. LinkedIn) profiles showing sufficient relevant experience? Is their participation transparent?

3.0
N/A
3 - Mostly assembled and committed.
Team Skill Set Relevance

Does the amount of talent and skill in each area seem to fit the project requirements?

4.0
N/A
4 - Well suited to project requirements.
Team Skill Set Balance

Is the team well-rounded (biz/tech/blockchain)? Is there sufficient talent and skill in all areas of required development?

4.0
N/A
4 - Good, sufficient for each aspect.
Company and Team Score:
3.8

Token Sale

OmiX Token
Total supply: 3 Billion OmiX
Token Price: n/a
Hard Cap: n/a
Min Cap: n/a

Token Allocation
33% ICO
20% Growth Pool
20% Reserve
14% Founders
10% Advisors
03% Community

ICO Proceeds Distribution
23% Laboratories
21% Marketing
20% Platform Development
11% Operations
10% R&D
06% Data Storage
05% Legal
02% Sequencing PoC

Social Media Presence & Following
There is solid community engagment and reception.

Category Breakdown
Raise Amount Max

Is there a clear cap? Is the maximum raise amount modestly sufficient (as opposed to either greedy or insufficient)?

2.0
N/A
2 - Somewhat greedy or unrelated to plans.
Raise Amount Min

Is the minimum raise reasonable considering the development plan? Are there raise-amount dependent milestones?

2.0
N/A
2 - Only loosely related to plans.
Fund Allocation

Is fund distribution and allocation reasonable and justified?

4.0
N/A
4 - Well defined and reasonable.
Token Allocation

Is the ratio of tokens sold to those kept reasonable? Does it prevent the company from having too much control?

2.0
N/A
2 - Unclear or suspicious.
Media Presence and Following

Is the sale being talked about in Reddit, Bitcointalk, Social Media, Medium, etc.? Is information available and accessible? Is there interest?

4.0
N/A
4 - Solid exposure and interest, good impression.
Token Sale Score:
2.8

Use this code to share the ratings on your website